Antitumor agents with the use of HSV
US7384627B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 2, 2003 |
| Grant date | Jun 10, 2008 |
| Priority date | — |
| Expiry date | Jul 21, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/16661
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
It is intended to provide highly safe antitumor agents which exhibit an antitumor effect on human remote tumors such as metastatic tumors too and by which an antitumor immune reaction enabling an immune therapy for cancer can be induced, tumor immunity inducers, T cell activators, dendritic cell activators, a method of treating cancer using the same, etc. Inactivated herpes simplex virus (inactivated HSV), herpes simplex virus glycoprotein D (HSVgD), etc. are employed as the active ingredients of antitumor agents, tumor immunity inducers, T cell activators or dendritic cell activators. As a specific example of the treatment for the above-described inactivation, citation may be made of a combination of UV-irradiation using ultraviolet light at 254 nm at 4 J/m2 for 30 minutes with heating at 56° C. for 30 minutes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.